219 related articles for article (PubMed ID: 35041929)
1. Targeted Genotyping in Clinical Pharmacogenomics: What Is Missing?
Lopes JL; Harris K; Karow MB; Peterson SE; Kluge ML; Kotzer KE; Lopes GS; Larson NB; Bielinski SJ; Scherer SE; Wang L; Weinshilboum RM; Black JL; Moyer AM
J Mol Diagn; 2022 Mar; 24(3):253-261. PubMed ID: 35041929
[TBL] [Abstract][Full Text] [Related]
2. Results of the implementation of a pharmacogenomics platform based on NGS technologies. Combining clinical and research approaches.
Ramudo-Cela L; Busto-Fernández F; Outeda-Macías M; Antolín S; Calvo-Martínez L; Martín-Herranz I
Farm Hosp; 2021 Dec; 45(7):11-37. PubMed ID: 35379108
[TBL] [Abstract][Full Text] [Related]
3. Analytical Validation of a Computational Method for Pharmacogenetic Genotyping from Clinical Whole Exome Sequencing.
Ly RC; Shugg T; Ratcliff R; Osei W; Lynnes TC; Pratt VM; Schneider BP; Radovich M; Bray SM; Salisbury BA; Parikh B; Sahinalp SC; Numanagić I; Skaar TC
J Mol Diagn; 2022 Jun; 24(6):576-585. PubMed ID: 35452844
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomic profile of a central European urban random population-Czech population.
Proietti R; Maranho Neto GA; Kunzova S; Lo Re O; Ahola-Olli A; Heliste J; Gonzalez-Rivas JP; Vinciguerra M
PLoS One; 2023; 18(4):e0284386. PubMed ID: 37079615
[TBL] [Abstract][Full Text] [Related]
5. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
6. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.
Pratt VM; Zehnbauer B; Wilson JA; Baak R; Babic N; Bettinotti M; Buller A; Butz K; Campbell M; Civalier C; El-Badry A; Farkas DH; Lyon E; Mandal S; McKinney J; Muralidharan K; Noll L; Sander T; Shabbeer J; Smith C; Telatar M; Toji L; Vairavan A; Vance C; Weck KE; Wu AH; Yeo KT; Zeller M; Kalman L
J Mol Diagn; 2010 Nov; 12(6):835-46. PubMed ID: 20889555
[TBL] [Abstract][Full Text] [Related]
7. Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing and a Customized CYP2D6 Genotyping Cascade.
Ji Y; Skierka JM; Blommel JH; Moore BE; VanCuyk DL; Bruflat JK; Peterson LM; Veldhuizen TL; Fadra N; Peterson SE; Lagerstedt SA; Train LJ; Baudhuin LM; Klee EW; Ferber MJ; Bielinski SJ; Caraballo PJ; Weinshilboum RM; Black JL
J Mol Diagn; 2016 May; 18(3):438-445. PubMed ID: 26947514
[TBL] [Abstract][Full Text] [Related]
8. Nine-gene pharmacogenomics profile service: The Mayo Clinic experience.
Matey ET; Ragan AK; Oyen LJ; Vitek CR; Aoudia SL; Ragab AK; Fee-Schroeder KC; Black JL; Moyer AM; Nicholson WT; Shrestha S; McAllister TM; Sinnwell JP; Faubion SS; Lazaridis KN
Pharmacogenomics J; 2022 Feb; 22(1):69-74. PubMed ID: 34671112
[TBL] [Abstract][Full Text] [Related]
9. Computational pharmacogenotype extraction from clinical next-generation sequencing.
Shugg T; Ly RC; Osei W; Rowe EJ; Granfield CA; Lynnes TC; Medeiros EB; Hodge JC; Breman AM; Schneider BP; Sahinalp SC; Numanagić I; Salisbury BA; Bray SM; Ratcliff R; Skaar TC
Front Oncol; 2023; 13():1199741. PubMed ID: 37469403
[TBL] [Abstract][Full Text] [Related]
10. Characterization of 137 Genomic DNA Reference Materials for 28 Pharmacogenetic Genes: A GeT-RM Collaborative Project.
Pratt VM; Everts RE; Aggarwal P; Beyer BN; Broeckel U; Epstein-Baak R; Hujsak P; Kornreich R; Liao J; Lorier R; Scott SA; Smith CH; Toji LH; Turner A; Kalman LV
J Mol Diagn; 2016 Jan; 18(1):109-23. PubMed ID: 26621101
[TBL] [Abstract][Full Text] [Related]
11. Projected Prevalence of Actionable Pharmacogenetic Variants and Level A Drugs Prescribed Among US Veterans Health Administration Pharmacy Users.
Chanfreau-Coffinier C; Hull LE; Lynch JA; DuVall SL; Damrauer SM; Cunningham FE; Voight BF; Matheny ME; Oslin DW; Icardi MS; Tuteja S
JAMA Netw Open; 2019 Jun; 2(6):e195345. PubMed ID: 31173123
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project.
Pratt VM; Turner A; Broeckel U; Dawson DB; Gaedigk A; Lynnes TC; Medeiros EB; Moyer AM; Requesens D; Vetrini F; Kalman LV
J Mol Diagn; 2021 Aug; 23(8):952-958. PubMed ID: 34020041
[TBL] [Abstract][Full Text] [Related]
13. Fetal pharmacogenomics: A promising addition to complex neonatal care.
Raymond M; Critchlow E; Rice SM; Wodoslawsky S; Berger SI; Hegde M; Empey PE; Al-Kouatly HB
Mol Genet Metab; 2022; 137(1-2):140-145. PubMed ID: 36029725
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
15. Development and Cross-Validation of High-Resolution Melting Analysis-Based Cardiovascular Pharmacogenetics Genotyping Panel.
Langaee T; El Rouby N; Stauffer L; Galloway C; Cavallari LH
Genet Test Mol Biomarkers; 2019 Mar; 23(3):209-214. PubMed ID: 30758238
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenomics implementation in cardiovascular disease in a highly diverse population: initial findings and lessons learned from a pilot study in United Arab Emirates.
Al-Mahayri ZN; Khasawneh LQ; Alqasrawi MN; Altoum SM; Jamil G; Badawi S; Hamza D; George L; AlZaabi A; Ouda H; Al-Maskari F; AlKaabi J; Patrinos GP; Ali BR
Hum Genomics; 2022 Sep; 16(1):42. PubMed ID: 36154845
[TBL] [Abstract][Full Text] [Related]
17. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
[TBL] [Abstract][Full Text] [Related]
18. Precision medicine in cardiovascular therapeutics: Evaluating the role of pharmacogenetic analysis prior to drug treatment.
Ingelman-Sundberg M; Pirmohamed M
J Intern Med; 2024 May; 295(5):583-598. PubMed ID: 38343077
[TBL] [Abstract][Full Text] [Related]
19. Genotype and phenotype concordance for pharmacogenetic tests through proficiency survey testing.
Wu AH
Arch Pathol Lab Med; 2013 Sep; 137(9):1232-6. PubMed ID: 23991737
[TBL] [Abstract][Full Text] [Related]
20. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients.
Dong OM; Li A; Suzuki O; Oni-Orisan A; Gonzalez R; Stouffer GA; Lee CR; Wiltshire T
Pharmacogenomics; 2018 Jun; 19(9):771-782. PubMed ID: 29793377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]